Skip to main content
Erschienen in: Digestive Diseases and Sciences 11/2022

04.03.2022 | Original Article

Spontaneous Seroclearance Is Associated with Lower Liver Fibrosis in Treatment-Naïve Chronic Hepatitis B Patients

verfasst von: Sammy Saab, Nguyen Pham, William Wu, Long Dang, An Dang, Jung Yum, Kisub Shim, Steven Wu

Erschienen in: Digestive Diseases and Sciences | Ausgabe 11/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Chronic hepatitis B virus (HBV) is a major public health concern. Transient elastrography (TE) is a reliable method in assessing hepatic fibrosis in patients with liver disease. We assess the potential clinical associations between HBsAg seroclearance and the severity of liver fibrosis.

Methods

We retrospectively performed a matched analysis of 23 consecutive HBsAg seroclearance patients who underwent TE between March 2008 and August 2021 from a community practice at a 1:3 ratio based on clinic visit date. Baseline laboratory and clinical data were collected. Fisher’s exact test and Chi-square test for proportions, and Wilcoxon rank-sum test for median were performed.

Results

Twenty-three cases and 69 controls were identified. Median follow up (interquartile range) for the cases and controls was 24,314 (1402) and 2332 (1587) days (p  =  0.15), respectively. All patients were Asian. Median age of cases was higher than controls (64 vs 52, p < 0.01, respectively). While most comorbidities were similar, diabetes and hyperlipidemia were more prevalent in cases. Baseline HBV DNA was detectable in 78% of cases and 97% of controls (p < 0.01). More cases had baseline HBsAg titers below 1000 IU/mL than controls (81% vs 8.7%, p < 0.01). Other baseline laboratory values were similar. Few cases had a fibrosis score greater than 1, while control had over a quarter of patients with a fibrosis score of 2 or 3.

Conclusion

Spontaneous HBsAg seroclearance remains rare in patients with chronic HBV infection. It is associated with low baseline HBsAg, and lower level of liver fibrosis as detected by TE.
Literatur
1.
Zurück zum Zitat Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol. 2004;38:S158–S168.CrossRef Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol. 2004;38:S158–S168.CrossRef
2.
Zurück zum Zitat World Health Organization (WHO). Global Hepatitis Report, 2017. Geneva, Switzerland: World Health Organization; 2017. World Health Organization (WHO). Global Hepatitis Report, 2017. Geneva, Switzerland: World Health Organization; 2017.
3.
Zurück zum Zitat Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of Chronic Hepatitis B Virus Infection in the United States. Am J Gastroenterol. 2020;115:1429–1438.CrossRef Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of Chronic Hepatitis B Virus Infection in the United States. Am J Gastroenterol. 2020;115:1429–1438.CrossRef
4.
Zurück zum Zitat Terrault NA, Lok ASF, McMahon BJ et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–1599.CrossRef Terrault NA, Lok ASF, McMahon BJ et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–1599.CrossRef
7.
Zurück zum Zitat Chien J, Liu J, Lee MH et al. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis. J Gastroenterol Hepatol. 2016;31:1971–1977.CrossRef Chien J, Liu J, Lee MH et al. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis. J Gastroenterol Hepatol. 2016;31:1971–1977.CrossRef
8.
Zurück zum Zitat Song C, Zhu J, Ge Z et al. Spontaneous Seroclearance of Hepatitis B Surface Antigen and Risk of Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2019;17:1204–1206.CrossRef Song C, Zhu J, Ge Z et al. Spontaneous Seroclearance of Hepatitis B Surface Antigen and Risk of Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2019;17:1204–1206.CrossRef
9.
Zurück zum Zitat Zhou K, Contag C, Whitaker E, Terrault N. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. Lancet Gastroenterol Hepatol. 2019;4:227–238.CrossRef Zhou K, Contag C, Whitaker E, Terrault N. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. Lancet Gastroenterol Hepatol. 2019;4:227–238.CrossRef
11.
Zurück zum Zitat Wong RJ, Nguyen MT, Trinh HN et al. Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study. J Viral Hepat. 2017;24:1089–1097.CrossRef Wong RJ, Nguyen MT, Trinh HN et al. Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study. J Viral Hepat. 2017;24:1089–1097.CrossRef
12.
Zurück zum Zitat Han ZG, Qie ZH, Qiao WZ. HBsAg spontaneous seroclearance in a cohort of HBeAg-seronegative patients with chronic hepatitis B virus infection. J Med Virol. 2016;88:79–85.CrossRef Han ZG, Qie ZH, Qiao WZ. HBsAg spontaneous seroclearance in a cohort of HBeAg-seronegative patients with chronic hepatitis B virus infection. J Med Virol. 2016;88:79–85.CrossRef
13.
Zurück zum Zitat Papatheodoridi M, Hadziyannis E, Berby F et al. Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B. J Viral Hepat. 2020;27:118–126.CrossRef Papatheodoridi M, Hadziyannis E, Berby F et al. Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B. J Viral Hepat. 2020;27:118–126.CrossRef
14.
Zurück zum Zitat Chen YC, Jeng WJ, Chu CM, Liaw YF. Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2012;10:297–302.CrossRef Chen YC, Jeng WJ, Chu CM, Liaw YF. Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2012;10:297–302.CrossRef
15.
Zurück zum Zitat Liu J, Yang HI, Lee MH et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010;139:474–482.CrossRef Liu J, Yang HI, Lee MH et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010;139:474–482.CrossRef
16.
Zurück zum Zitat Ferreira SC, Chachá SG, Souza FF et al. Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital. Ann Hepatol. 2014;13:762–770.CrossRef Ferreira SC, Chachá SG, Souza FF et al. Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital. Ann Hepatol. 2014;13:762–770.CrossRef
17.
Zurück zum Zitat Frulio N, Trillaud H. Ultrasound elastography in liver. Diagn Interv Imaging. 2013;94:515–534.CrossRef Frulio N, Trillaud H. Ultrasound elastography in liver. Diagn Interv Imaging. 2013;94:515–534.CrossRef
18.
Zurück zum Zitat Marcellin P, Ziol M, Bedossa P et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009;29:242–247.CrossRef Marcellin P, Ziol M, Bedossa P et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009;29:242–247.CrossRef
19.
Zurück zum Zitat Varbobitis IC, Siakavellas SI, Koutsounas IS et al. Reliability and applicability of Two-Dimensional shear-wave elastography for the evaluation of liver stiffness. Eur J Gastroenterol Hepatol. 2016;28:1204–1209.CrossRef Varbobitis IC, Siakavellas SI, Koutsounas IS et al. Reliability and applicability of Two-Dimensional shear-wave elastography for the evaluation of liver stiffness. Eur J Gastroenterol Hepatol. 2016;28:1204–1209.CrossRef
20.
Zurück zum Zitat Pavlov CS, Casazza G, Nikolova D, Tsochatzis E, Burroughs AK, Ivashkin VT, Gluud C. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No.: CD010542. DOI: https://doi.org/10.1002/14651858.CD010542.pub2. Accessed 07 July 2021. Pavlov CS, Casazza G, Nikolova D, Tsochatzis E, Burroughs AK, Ivashkin VT, Gluud C. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No.: CD010542. DOI: https://​doi.​org/​10.​1002/​14651858.​CD010542.​pub2. Accessed 07 July 2021.
21.
Zurück zum Zitat de Lédinghen V, Vergniol J, Barthe C et al. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus. Aliment Pharmacol Ther. 2013;37:979–988.CrossRef de Lédinghen V, Vergniol J, Barthe C et al. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus. Aliment Pharmacol Ther. 2013;37:979–988.CrossRef
22.
Zurück zum Zitat Wong GL, Chan HL, Yu Z et al. Noninvasive assessments of liver fibrosis with transient elastography and Hui index predict survival in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2015;30:582–590.CrossRef Wong GL, Chan HL, Yu Z et al. Noninvasive assessments of liver fibrosis with transient elastography and Hui index predict survival in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2015;30:582–590.CrossRef
23.
Zurück zum Zitat Fung J, Lai CL, Seto WK, Wong DK, Yuen MF. Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. J Viral Hepat. 2011;18:738–744.CrossRef Fung J, Lai CL, Seto WK, Wong DK, Yuen MF. Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. J Viral Hepat. 2011;18:738–744.CrossRef
24.
Zurück zum Zitat Fung J et al. Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. J Viral Hepatitis 2011;18:e200–e205.CrossRef Fung J et al. Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. J Viral Hepatitis 2011;18:e200–e205.CrossRef
25.
Zurück zum Zitat Whelton Paul K, Carey Robert M, Aronow Wilbert S et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–e115.PubMed Whelton Paul K, Carey Robert M, Aronow Wilbert S et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–e115.PubMed
26.
Zurück zum Zitat Grundy SM, Stone NJ, Bailey AL et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:e285–e350.CrossRef Grundy SM, Stone NJ, Bailey AL et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:e285–e350.CrossRef
27.
Zurück zum Zitat Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112:18–35.CrossRef Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112:18–35.CrossRef
28.
Zurück zum Zitat Chen QY, Wang XY, Harrison TJ et al. HBsAg may reappear following reactivation in individuals with spontaneous HBsAg seroclearance 8 years previously. Epidemiol Infect. 2017;145:728–738.CrossRef Chen QY, Wang XY, Harrison TJ et al. HBsAg may reappear following reactivation in individuals with spontaneous HBsAg seroclearance 8 years previously. Epidemiol Infect. 2017;145:728–738.CrossRef
29.
Zurück zum Zitat Chu CM, Lin DY, Liaw YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection? Int J Obes (Lond). 2007;31:871–875.CrossRef Chu CM, Lin DY, Liaw YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection? Int J Obes (Lond). 2007;31:871–875.CrossRef
30.
Zurück zum Zitat Chu CM, Lin DY, Liaw YF. Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without. Dig Dis Sci. 2013;58:275–281.CrossRef Chu CM, Lin DY, Liaw YF. Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without. Dig Dis Sci. 2013;58:275–281.CrossRef
31.
Zurück zum Zitat Li J, Yang HI, Yeh ML et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B. J Infect Diseases. 2021;224:294–302.CrossRef Li J, Yang HI, Yeh ML et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B. J Infect Diseases. 2021;224:294–302.CrossRef
32.
Zurück zum Zitat Song A, Wang X, Lu J et al. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: a meta-analysis. J Viral Hepat. 2021;28:601–612.CrossRef Song A, Wang X, Lu J et al. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: a meta-analysis. J Viral Hepat. 2021;28:601–612.CrossRef
33.
Zurück zum Zitat Kuang XJ, Jia RR, Huo RR et al. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Viral Hepat. 2018;25:1026–1037.CrossRef Kuang XJ, Jia RR, Huo RR et al. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Viral Hepat. 2018;25:1026–1037.CrossRef
34.
Zurück zum Zitat Kim JH, Lee YS, Lee HJ et al. HBsAg seroclearance in chronic hepatitis B: implications for hepatocellular carcinoma. J Clin Gastroenterol. 2011;45:64–68.CrossRef Kim JH, Lee YS, Lee HJ et al. HBsAg seroclearance in chronic hepatitis B: implications for hepatocellular carcinoma. J Clin Gastroenterol. 2011;45:64–68.CrossRef
35.
Zurück zum Zitat O’Rourke JM et al. Carcinogenesis on the background of liver fibrosis: implications for the management of hepatocellular cancer. W J Gastroenterol. 2018;24:4436–4447.CrossRef O’Rourke JM et al. Carcinogenesis on the background of liver fibrosis: implications for the management of hepatocellular cancer. W J Gastroenterol. 2018;24:4436–4447.CrossRef
36.
Zurück zum Zitat Sun YM, Chen SY, You H. Regression of liver fibrosis: evidence and challenges. Chin Med J (Engl). 2020;133:1696–1702.CrossRef Sun YM, Chen SY, You H. Regression of liver fibrosis: evidence and challenges. Chin Med J (Engl). 2020;133:1696–1702.CrossRef
38.
Zurück zum Zitat Poynard T, Moussalli J, Munteanu M et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013;59:675–683.CrossRef Poynard T, Moussalli J, Munteanu M et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013;59:675–683.CrossRef
Metadaten
Titel
Spontaneous Seroclearance Is Associated with Lower Liver Fibrosis in Treatment-Naïve Chronic Hepatitis B Patients
verfasst von
Sammy Saab
Nguyen Pham
William Wu
Long Dang
An Dang
Jung Yum
Kisub Shim
Steven Wu
Publikationsdatum
04.03.2022
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 11/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-022-07402-1

Weitere Artikel der Ausgabe 11/2022

Digestive Diseases and Sciences 11/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.